✦ LIBER ✦

Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: A single hospital experience

✍ Scribed by Pratt, Charles B.; Luo, Xiaolong; Fang, Lei; Marina, Neyssa; Avery, Loraine; Furman, Wayne L.

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 411 KB
Volume: 27
Category: Article
ISSN: 0098-1532
DOI: 10.1002/(sici)1096-911x(199609)27:3<145::aid-mpo2>3.0.co;2-e

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ifosfamide/etoposide combination in the

Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study

✍ Faith H. Kung; Charles B. Pratt; Roger A. Vega; Norman Jaffe; Douglas Strother; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 509 KB

Background. The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children. Methods. Between August 1987 and November 1990, 311 children with recurrent or resistant malignant solid tumors were treated by inves

High histologic and overall response to

High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors : The Bambino Gesù Children's Hospital experience

✍ Giuseppe Maria Milano; Raffaele Cozza; Ilaria Ilari; Luigi De Sio; Renata Boldri 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

A Phase I study of granulocyte-macrophag

A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors : A report of the Children's Cancer Group

✍ Mitchell S. Cairo; Mark D. Krailo; Joel A. Weinthal; Rita Secola; Sharon Bergero 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 3 views

## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a

Erratum: Milano GM, Cozza R, Ilari I, et

Erratum: Milano GM, Cozza R, Ilari I, et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors: The Bambino Gesù Children's Hospital experience. Cancer. 2006;106(8):1838–45.

📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 24 KB 👁 1 views